TY - JOUR
T1 - Epoxyeicosatrienoic acids - Novel mechanism and pharmacological therapy of chronic renocardiac syndrome
AU - Huang, Hui
AU - Chen, Jie
AU - Lin, Tianxin
AU - Wang, Tong
AU - Tang, Yi
AU - Dong, Yanbin
AU - Wang, Jingfeng
N1 - Funding Information:
Supported by National Natural Science Foundation of China (30700304 and 30973207) to Hui Huang, 30900478 to Yi Tang, and Natural Science Foundation of Guangdong Province China (9151008901000105) to Hui Huang.
Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/4
Y1 - 2011/4
N2 - Cardiorenal syndromes were defined and classified recently, but the mechanism of chronic renocardiac syndrome remains disputed. Theories about chronic renocardiac syndrome cannot offer a convincing explanation for it. As a result, the current therapies of chronic renocardiac syndrome do not contribute to a satisfied prognosis. Epoxyeicosatrienoic acids, the products of arachidonic acid metabolized by cytochrome P450 enzymes, play an important role in the maintenance of renal hemodynamics, and regulation of renal, cardiac, and vascular function with antihypertensive and anti-inflammatory properties. It is well documented that down-regulation of epoxyeicosatrienoic acids might be involved in alterations in various pathophysiological states, including hypertension, uremia and hepatorenal syndrome. Likewise, epoxyeicosatrienoic acids were reduced in heart failure and renal dysfunction. This leads to the proposed hypothesis that epoxyeicosatrienoic acids down-regulation may be the novel mechanism of chronic renocardiac syndrome. These findings suggest that manipulation of epoxyeicosatrienoic acid levels could be a novel pharmacological therapy strategy for chronic renocardiac syndrome.
AB - Cardiorenal syndromes were defined and classified recently, but the mechanism of chronic renocardiac syndrome remains disputed. Theories about chronic renocardiac syndrome cannot offer a convincing explanation for it. As a result, the current therapies of chronic renocardiac syndrome do not contribute to a satisfied prognosis. Epoxyeicosatrienoic acids, the products of arachidonic acid metabolized by cytochrome P450 enzymes, play an important role in the maintenance of renal hemodynamics, and regulation of renal, cardiac, and vascular function with antihypertensive and anti-inflammatory properties. It is well documented that down-regulation of epoxyeicosatrienoic acids might be involved in alterations in various pathophysiological states, including hypertension, uremia and hepatorenal syndrome. Likewise, epoxyeicosatrienoic acids were reduced in heart failure and renal dysfunction. This leads to the proposed hypothesis that epoxyeicosatrienoic acids down-regulation may be the novel mechanism of chronic renocardiac syndrome. These findings suggest that manipulation of epoxyeicosatrienoic acid levels could be a novel pharmacological therapy strategy for chronic renocardiac syndrome.
UR - http://www.scopus.com/inward/record.url?scp=79952315682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952315682&partnerID=8YFLogxK
U2 - 10.1016/j.mehy.2010.12.015
DO - 10.1016/j.mehy.2010.12.015
M3 - Article
C2 - 21333454
AN - SCOPUS:79952315682
SN - 0306-9877
VL - 76
SP - 550
EP - 552
JO - Medical Hypotheses
JF - Medical Hypotheses
IS - 4
ER -